MM14195 - National Fee Schedule for Vaccine Administration: October 2025 Update
We approved AVTOZMA® (tocilizumab-anoh), a biosimilar to ACTEMRA® (tocilizumab), to treat:
●
Rheumatoid arthritis
●
Giant cell arteritis
●
Polyarticular juvenile idiopathic arthritis
●
Systemic juvenile idiopathic arthritis
●
COVID-19
We established HCPCS Level II code Q0237 to describe AVTOZMA® for post-exposure prophylaxis or treating COVID-19 and associated administrative codes effective January 24, 2025. HCPCS Level II codes Q0237, M0237, and M0238 (see descriptors below) have the same effective date as FDA approval to align with appropriate Medicare payment policies.
Issued by: Centers for Medicare & Medicaid Services (CMS)
Issue Date: September 02, 2025
DISCLAIMER: The contents of this database lack the force and effect of law, except as authorized by law (including Medicare Advantage Rate Announcements and Advance Notices) or as specifically incorporated into a contract. The Department may not cite, use, or rely on any guidance that is not posted on the guidance repository, except to establish historical facts.